Moderna, Inc. (NASDAQ: MRNA) has announced a significant milestone in its global efforts to combat COVID-19 by securing a contract with Brazil’s Ministry of Health (Ministério da Saúde). The contract entails supplying Moderna’s mRNA COVID-19 vaccine as a crucial component of Brazil’s 2024 national vaccination campaign against the virus. This development follows the approval of Moderna’s COVID-19 vaccine by the Brazilian Health Regulatory Agency (ANVISA) in March 2024. Moderna’s vaccine, which encodes the spike protein of the XBB.1.5 sublineage of SARS-CoV-2, is approved for active immunization against COVID-19 in both children aged six months and adults.
Stéphane Bancel, Chief Executive Officer of Moderna, expressed pride in partnering with Brazil’s Ministry of Health, emphasizing the company’s commitment to global health and support for Brazil’s efforts to safeguard its population against COVID-19. The agreement underscores Moderna’s dedication to assisting nations worldwide in confronting the pandemic.
Under the terms of the contract, Moderna is set to deliver 12.5 million doses of its mRNA COVID-19 vaccine in the second quarter of 2024. This delivery marks a significant stride in Brazil’s ongoing battle against COVID-19 and highlights the mutual commitment of Moderna and the Ministry of Health to public health initiatives and national immunization campaigns. The collaboration is expected to strengthen Brazil’s vaccination campaign and contribute to the global fight against COVID-19.
Given the evolving nature of the virus, global health authorities have recommended updating COVID-19 vaccines to ensure efficacy against prevailing variants. Moderna has responded to this recommendation by developing a monovalent XBB.1.5 vaccine candidate, supported by preclinical and clinical data demonstrating its efficacy against XBB sublineages and currently circulating strains, including JN.1.
Moderna, known for its pioneering work in mRNA medicine, has played a pivotal role in transforming disease treatment and prevention methods. The company’s mRNA platform has facilitated the rapid development of therapeutics and vaccines for various diseases, including COVID-19. Committed to revolutionizing human health through innovative mRNA medicines, Moderna continues to strive for global impact.
The press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks, uncertainties, and factors beyond Moderna’s control, which could cause actual results to differ materially from those expressed or implied. Moderna disclaims any obligation to update these forward-looking statements in light of new information or future events.
For more information about Moderna, visit modernatx.com and follow the company on social media platforms.
